 | ||
| Your Chance for Access Ends Tonight Zacks Member, Yesterday, I notified you of a unique insider buy that could prove very lucrative for Zacks members who respond quickly. Two insiders poured in a total of $700,212.59 from their own pockets to buy shares of their own stock. Something's up with their large-cap pharmaceutical company. Perhaps there's positive news coming out of a current FDA drug trial. Maybe it's something no one else sees. But one thing is certain: These insiders expect their stock to go up in price. Of course, key officials know more about their companies than you, I, or any analyst ever could. This unfair advantage is why the law requires them to report within 48 hours when they buy substantial shares of their own companies. Our Insider Trader portfolio closely monitors these reports. We then combine insider buy signals with the Zacks Rank and other indicators to find stocks with outstanding gain potential. The above-mentioned stock is a strong company in a top industry. With new drugs in the pipeline, the sky could be the limit. Now is the time to follow the insiders and join the party. Check out this and other selected insider trades right now » Important: This is your last day to see these exciting opportunities. Insider Trader closes to public access Sunday, December 1 - midnight tonight. Good Investing,
P.S. Bonus Special Report. Today is also the last day to download Zacks' 5 Stocks Set to Double free of charge. Don't miss 5 stocks that our experts predict could grow +100% or more in the next 12 months. | ||
 | ||
| This free resource is being sent by Zacks.com. We look for investment resources and inform you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer. Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research is not a licensed securities dealer, broker or US investment adviser or investment bank. The Zacks #1 Rank Performance covers the period beginning on January 1, 1988 through November 4, 2019. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank #1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed above. Zacks Emails Zacks Investment Research |
没有评论:
发表评论